VICTORIA, BC / ACCESSWIRE / February 24, 2020 / Erin Ventures Inc. ("Erin" or the "Company") (TSXV:EV) announces that, subject to the approval of the TSX Venture Exchange (the "TSXV"), it intends to complete a private placement offering of up to 10,000,000 units of the Company ("Units") at a price of $0.05 per Unit for gross proceeds of up to $500,000.00 (the "Offering"). Additionally, Erin announces the proposed issuance of Units to certain holders (the "Debenture Holders") of the outstanding amended and restated 12% interest-bearing convertible debentures issued on April 10, 2015, July 14, 2015, and November 3, 2015 (collectively, the "Debentures") in full and final satisfaction of the Company's obligations under the Debentures, pursuant to the terms of debt settlement agreements between the Company and each Debenture Holder (the "Shares for Debt Settlement").

Private Placement

Each Unit will be comprised of one (1) common share in the capital of the Company (a "Share") and one (1) common share purchase warrant (each, a "Warrant"). Each Warrant will have a three (3) year term (the "Exercise Period") and will be exercisable into one (1) Share at a price of $0.075 in the first year and $0.10 thereafter per Share over the Exercise Period.

The Offering will be on a private placement basis pursuant to prospectus exemptions of applicable securities laws and is subject to final acceptance by the TSXV. Depending on demand and regulatory requirements, a portion of the Offering may be made to existing security holders of Company ("Shareholders") in accordance with the provisions of the existing shareholder exemption (the "Existing Shareholder Exemption") pursuant to BC Instrument 45-534 (the Existing Shareholder Exemption is not available in Ontario or Newfoundland and Labrador). In addition to conducting the Offering pursuant to the Existing Shareholder Exemption, Units will be offered to accredited investors, close personal friends and business associates of directors and officers of the Company, and certain investors who have been advised on the suitability of their investment by registered investment dealers (the "Registered Advisor Exemption").

The Company has set February 21, 2020 as the record date for the purpose of determining shareholders entitled to purchase Units relying on the Existing Shareholder Exemption. The aggregate acquisition cost to a subscriber relying on the Existing Shareholder Exemption cannot exceed $15,000 in a 12-month period unless the subscriber has obtained advice from a registered investment dealer regarding the suitability of the investment.

Unless the Company determines to increase the gross proceeds of the Offering and receives TSXV approval for such increase, if subscriptions by existing Shareholders exceed the maximum number of Units proposed to be distributed after having first satisfied the subscriptions of those subscribers relying on other prospectus exemptions referred to herein, subscribers relying on the Existing Shareholder Exemption will be entitled to a pro rata portion of the balance of Units available under the Offering.

Existing Shareholders are directed to contact the Company for further information concerning subscriptions for Units pursuant to the Existing Shareholder Exemption, as follows:

Contact person: Blake Fallis
Telephone: 1-250- 384-1999 or 1-888-289-3746
Email: blake@erinventures.com

Shares for Debt Settlement

Erin will issue Units at a value of $0.05 per Unit in full and final satisfaction of the principal and aggregate interest payments owed under the Debentures and each Debenture will be returned to the Company for cancellation. If each outstanding Debenture Holder enters into a Shares for Debt Settlement, Erin anticipates issuing a total of 6,820,000 Units representing the aggregate principal owed to the Debenture Holders and at least 190,587 Units representing the aggregate interest accrued as of the date hereof. The amount of interest settled will equal the total amount of interest accrued as of the date of closing of the Shares for Debt Settlement. Units issued in connection with the Shares for Debt Settlement will be in addition to the Units issued in connection with the Offering.

The Units, and any Warrant Shares issued, will be subject to a four-month hold period. The proposed Shares for Debt Settlement and Offering are subject to the approval of the TSX Venture Exchange.

In accordance with the requirements under the Existing Shareholder Exemption and the Registered Advisor Exemption, there is no material fact or material change about the issuer that has not been generally disclosed.

On behalf of the Board of Directors,

Blake Fallis, General Manager

About Erin Ventures

Erin Ventures Inc. is an international mineral exploration and development company with boron assets in Serbia. Headquartered in Victoria, B.C., Canada, Erin's shares are traded on the TSX Venture Exchange under the symbol "EV" and the OTCQB Venture Market under the symbol "ERVFF". For detailed information please see Erin's website at www.erinventures.com or the Company's filed documents at www.sedar.com.

For further information, please contact:

Erin Ventures Inc.
Blake Fallis, General Manager
Phone: 1-250- 384-1999 or 1-888-289-3746
www.erinventures.com
645 Fort Street, Suite 203
Victoria BC V8W1G2
Canada

Erin's Public Quotations:

Canada
TSX Venture: EV
USA
OTCQB: ERVFF

Europe
Berlin Stock Exchange: EKV

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements:

This release contains forward looking statements. The words "believe," "expect," "feel," "plan," "anticipate," "project," "could," "should" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties including, without limitation, variations in estimated costs, the failure to discover or recover economic grades of minerals, and the inability to raise the funds necessary, changes in external market factors including commodity prices, and other risks and uncertainties. Actual results could differ materially from the results referred to in the forward-looking statements.

SOURCE: Erin Ventures Inc.

ReleaseID: 577688

TORONTO, ON / ACCESSWIRE / February 24, 2020 / AirIQ Inc. ("AirIQ") (TSXV:IQ), a supplier of wireless asset management services, today announced that it has secured a further order for hardware and services totalling approximately CAD$110,000 from an existing major rental customer in the United States for AirIQ's electronic control module (ECM) solution.

"Although smaller than some of the previously announced orders, this order reflects the customer's ongoing commitment to AirIQ, and the engine diagnostic capabilities utilizing AirIQ Fleet™" stated Mike Robb, President and Chief Executive Officer of AirIQ. "We are excited that our business with this customer continues to grow as it supports customer satisfaction, which is one of our key performance indicators," continued Mr. Robb.

AirIQ's ECM device connects to the vehicle's electronic control module and delivers real time engine diagnostic codes to AirIQ's Web Application, AirIQ Fleet™. Customers can then view reports and set up notifications to monitor the health of their fleet, including engine, transmission and emissions related problems. This feature adds significant value to AirIQ's Fleet Management solution. By integrating a GPS device with diagnostic capability together with AirIQ's Web Application, customers can monitor their vehicle's engine performance to quickly identify issues, proactively perform maintenance and thereby decrease costs and increase safety, uptime and productivity.

About AirIQ

AirIQ currently trades on the TSX Venture Exchange under the symbol IQ. AirIQ is an intuitive web-based platform that provides fleet operators and vehicle owners with a suite of asset management solutions to reduce cost, improve efficiency and monitor, manage and protect their assets. Services are available online or via a mobile app, and include: instant vehicle locating, boundary notification, automated inventory reports, maintenance reminders, security alerts and vehicle disabling and unauthorized movement alerts. AirIQ's office is located in Pickering, Ontario, Canada. For additional information on AirIQ or its products and services, please visit the Company's website at www.airiq.com.

Forward-looking Statements

This news release contains forward-looking information based on management's best estimates and the current operating environment. These forward-looking statements are related to, but not limited to, AirIQ's operations, anticipated financial performance, business prospects and strategies. Forward-looking information typically contains statements with words such as "hope", "goal", "anticipate", "believe", "expect", "plan" or similar words suggesting future outcomes. These statements are based upon certain material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking statements, including AirIQ's perception of historical trends, current conditions and expected future developments as well as other factors management believes are appropriate in the circumstances. Such forward-looking statements are as of the date which such statement is made and are subject to a number of known and unknown risks, uncertainties and other factors, which could cause actual results or events to differ materially from future results expressed, anticipated or implied by such forward-looking statements. Such factors include, but are not limited to, changes in market and competition, technological and competitive developments and potential downturns in economic conditions generally. Therefore, actual outcomes may differ materially from those expressed in such forward-looking statements. Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Other than as may be required by law, AirIQ disclaims any intention or obligation to update or revise any such forward-looking statements, whether as a result of such information, future events or otherwise.

For more information please contact:

AirIQ Inc.
Michael Robb
President and Chief Executive Officer
(905) 831-6444
mrobb@airiq.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AirIQ Inc.

ReleaseID: 577611

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ:ADVM) Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/advm.

The investigation concerns whether Adverum and certain of its officers and/or directors have violated federal securities laws.

On September 12, 2019, Adverum issued a press release announcing clinical data from the OPTIC Phase 1 clinical trial of the Company's product ADVM-022 as a treatment for wet age-related macular degeneration. Among other data, Adverum disclosed that patients taking ADVM-022 suffered significant deterioration in their sight. On this news, Adverum's stock price fell $6.04 per share, or 50.33%, to close at $5.96 per share on September 12, 2019.

If you are aware of any facts relating to this investigation or purchased Adverum shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/advm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 577679

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Qudian Inc. (NYSE:QD)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/qudian-inc-loss-submission-form?prid=5515&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: December 13, 2018 to January 15, 2020

Allegations against QD include that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full-year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Geron Corporation (NASDAQ:GERN)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/geron-corporation-et-al-loss-submission-form?prid=5515&wire=1
Lead Plaintiff Deadline: March 23, 2020
Class Period: March 19, 2018 to September 26, 2018

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis

Westpac Banking Corporation (NYSE:WBK)

If you suffered a loss, contact us at http://www.wongesq.com/pslra-1/westpac-banking-corporation-loss-submission-form?prid=5515&wire=1
Lead Plaintiff Deadline: March 30, 2020
Class Period: November 11, 2015 to November 19, 2019

Allegations against WBK include that: (1) contrary to Australian law, the Company failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre ("AUSTRAC"); (2) the Company did not appropriately monitor and assess the ongoing money laundering and terrorism financing risks associated with movement of money into and out of Australia; (3) the Westpac did not pass on requisite information about the source of funds to other banks in the transfer chain; (4) despite being aware of the heightened risks, the Company did not carry out appropriate due diligence on transactions in South East Asia and the Philippines that had known financial indicators relating to child exploitation risks; (5) the Company's Anti-Money Laundering and Counter-Terrorism Financing Policy Program was inadequate to identify, mitigate and manage money laundering and terrorism financing risks; and (6) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more, contact Vincent Wong, Esq. either via e-mail vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 577672

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CPI Aerostructures, Inc.

("CPI" or the "Company") (NYSE:CVU) and certain of its officers on behalf of shareholders who purchased CPIsecurities between May 15, 2018 and February 14, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/cvu.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) CPI Aerostructures' financial statements included in the Company's Forms 10-Q for the first, second, and third quarters of 2018 and 2019 incorrectly applied generally accepted accounting principles and thus revenue, net income, retained earnings, and contract assets were overstated; (2) as a result, the financial statements included in the Form 10-Qs for 2018 and 2019 and the annual report on Form 10-K for 2018 could no longer be relied upon and required restatement; (3) CPI Aerostructures lacked adequate internal controls over financial reporting and effective disclosure controls and procedures as of the period during each reporting period of 2018; (4) CPI Aerostructures lacked effective disclosure controls and procedures during the third quarter of 2019; and (5) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint, you can visit the firm's site: www.bgandg.com/cvu, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in CVU, you have until April 24, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 577671

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Luckin Coffee Inc. (NASDAQ:LK)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/luckin-coffee-inc-loss-submission-form?prid=5514&wire=1
Lead Plaintiff Deadline: April 13, 2020
Class Period: November 13, 2019 to January 31, 2020

Allegations against LK include that: (i) certain of Luckin's financial performance metrics, including per-store per-day sales, net selling price per item, advertising expenses, and revenue contribution from "other products" were inflated; (ii) Luckin's financial results thus overstated the Company's financial health and were consequently unreliable; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

HP Inc. (NYSE:HPQ)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hp-inc-loss-submission-form?prid=5514&wire=1
Lead Plaintiff Deadline: April 20, 2020
Class Period: February 23, 2017 to October 3, 2019

According to the filed complaint, defendants knew that HP's "four-box" model for measuring its supplies business was severely deficient and not a strong predictor of supplies demand and outcomes because HP lacked telemetry data from its commercial printers and had to use unreliable and stagnant market share data to develop assumptions for the four-box model. The complaint further alleges that defendants knew the lack of telemetry data for commercial printing was a critical shortcoming of the four-box model because HP possessed telemetry data on its personal printing side and knew it was a necessary element for an accurate understanding of the supplies channel. As a result, the supplies inventory in the Company's channel exceeded demand by at least $100 million and HP's supplies revenue growth was grossly inflated.

Jeld-Wen Holding, Inc. (NYSE:JELD)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/jeld-wen-holding-inc-loss-submission-form?prid=5514&wire=1
Lead Plaintiff Deadline: April 20, 2020
Class Period: January 26, 2017 to October 15, 2018

Allegations against JELD include that: (1) the Company's products, including doors, did not compete against other manufacturers on price, contrary to Jeld-Wen's representations; (2) the market in which the Company sells its doors is not "highly competitive" as the Company claimed; (3) Jeld-Wen's strong margins and anticipated margin growth were not, as the Company claimed, attributed to changes they had made in Jeld-Wen's business operations and strategies; and (4) Jeld-Wen failed to disclose the Company's anti competitive conduct. Because of the foregoing, Defendants' statements about the Company's business, operations and prospects lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 577665

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Trulieve Cannabis Corp. (OTCQX:TCNNF) between September 25, 2018 and December 17, 2019, inclusive (the "Class Period"), of the important February 28, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Trulieve investors under the federal securities laws.

To join the Trulieve class action, go to http://www.rosenlegal.com/cases-register-1745.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or e-mail pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the Company overstated its mark-up on its biological assets; (2) therefore, Trulieve's reported gross profit was inflated; (3) Trulieve engaged in an undisclosed related party real estate sale with Defendant Rivers' husband; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class-action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 28, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1745.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll-free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT:
Laurence Rosen, Esq.
lrosen@rosenlegal.com
Phillip Kim, Esq.
pkim@rosenlegal.com
The Rosen Law Firm, P.A.
cases@rosenlegal.com
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
www.rosenlegal.com

SOURCE: Rosen Law Firm PA

ReleaseID: 577666

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of 500.com Limited (NYSE:WBAI) between April 27, 2018 and December 31, 2019, inclusive (the "Class Period"), of the important March 16, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for 500.com investors under the federal securities laws.

To join the 500.com class action, go to http://www.rosenlegal.com/cases-register-1750.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR'S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) 500.com executives and consultants engaged in a bribery scheme with Japanese officials in an effort to gain favor in a bid to run an upcoming Japanese casino resort; (2) consequently, 500.com was in violation of Japanese anti-bribery laws and its Code of Ethics; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1750.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

SOURCE: Rosen Law Firm

ReleaseID: 577668

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Genfit SA ("Genfit" or the Company") (NASDAQ:GNFT). Investors who purchased Genfit securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/gnft.

The investigation concerns whether Genfit and certain of its officers and/or directors have violated federal securities laws.

On February 21, 2020, post-market, Genfit issued a press release announcing a delay in the release of topline results from the Phase 3 RESOLVE-IT study evaluating the Company's lead drug elafibranor in patients with nonalcoholic steatohepatitis ("NASH") with fibrosis. Genfit stated that the delay was in order "to incorporate the latest FDA insights expected by the end of March" and that "[t]his decision has been taken to ensure that the latest thinking in the NASH field is properly captured so the Company can optimize elafibranor's NDA dossier at the time of submission." On this news, Genfit's stock price fell sharply during intraday trading on February 24, 2020.

If you are aware of any facts relating to this investigation, or purchased Genfit shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/gnft. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 577667

NEW YORK, NY / ACCESSWIRE / February 24, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dorman Products, Inc. ("Dorman" or the Company") (NASDAQ:DORM). Investors who purchased Dorman securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/dorm.

The investigation concerns whether Dorman and certain of its officers and/or directors have violated federal securities laws.

On February 24, 2020, Dorman issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 28, 2019. Among other results, Dorman announced fourth-quarter net sales of $239.6 million, down 8% compared to $260.3 million in the prior year, and diluted earnings per share in the quarter on a GAAP basis of $0.54, down 49% compared to $1.05 in the prior year. Dorman also disclosed that "[d]uring the fourth quarter, we recorded an estimated pre-tax charge of $2.8 million ($2.3 million after tax or $0.07 per diluted share) related to the underpayment of duties to U.S. Customs arising from the misclassification of certain imported products over a five-year period. The charge, which is expected to be one-time in nature, follows an internal review and the Company's notification to U.S. Customs of its election to submit to a voluntary prior disclosure process to rectify historical misclassifications and underpayment of duties, as previously reported in the Company's SEC filings. Since discovering the misclassifications, the Company has taken corrective actions with respect to the ongoing classification of products and payment of duties." On these disclosures, Dorman's stock price fell sharply during intraday trading on February 24, 2020.

If you are aware of any facts relating to this investigation or purchased Dorman shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/dorm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 577662